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Abstract
The aim of this paper is to develop a mathematical model capable of simulating the
metabolic response to a variety of mixed meals in fed and fasted conditions with
particular emphasis placed on the hepatic triglyceride element of the model. Model
validation is carried out using experimental data for the ingestion of three mixed com-
position meals over a 24-hour period. Comparison with experimental data suggests
the model predicts key plasma lipids accurately given a prescribed insulin profile. One
counter-intuitive observation to arise from simulations is that liver triglyceride ini-
tially decreases when a high fat meal is ingested, a phenomenon potentially explained
by the carbohydrate portion of the meal raising plasma insulin.
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the chronic build up of excess lipids in
the liver. NAFLD spans simple hepatic steatosis (HS) to hepatic steatosis accom-
panied by inflammation, termed non-alcoholic steatohepatitis (NASH), a condition
that may progress to fibrosis and cirrhosis of the liver. Angulo & Lindor [6] report
the prevalence of NAFLD varies with estimates of 10-24 % of the populations in de-
veloped nations being normal. Of these individuals, 25% may progress to the more
serious NASH. Prevalence of NAFLD amongst the obese is significantly higher (75%),
as is the prevalence in individuals with type 2 diabetes. With an increasing number of
cases of NAFLD being diagnosed, a better understanding of the pathology of hepatic
steatosis is required.
A number of pathways interact directly in the deposition and removal of liver lipids.
Beta-oxidation of fatty acids, for use as a fuel source within the liver, represents a
significant contribution to the disposal of hepatic lipids. Whilst hepatic oxidation
of fatty acids is unchanged between subjects with high and low liver fat [34], a dif-
ference between obese and lean individuals has been observed by Hodson et al [24].
It was found that obese individuals had increased hepatic fatty acid oxidation over
lean individuals in the postprandial period, potentially explained by a reduced sup-
pression of beta-oxidation due to hepatic insulin resistance. Synthesis and secretion
of very low-density lipoproteins (VLDL) provide a means for the liver to remove ex-
cess triglycerides (TAG) from cytosolic stores. This process is heavily influenced by
insulin with both the number and size of particles secreted into the blood affected.
Once much of the TAG has been removed from plasma VLDL by other tissues, the
remnant particles, low density lipoproteins (LDL), are returned to the liver. Sim-
ilarly, intestinally-derived chylomicrons delivering lipids from the gut have most of
their TAG removed before the remnant particle is taken up by the liver. The direct
contribution from chylomicron remnants to liver fat is estimated to be in the region of
7.2% of total liver fat sources [14]. Ordinarily, de novo lipogenesis (DNL) represents a
pathway for the disposal of large volumes of carbohydrates through the conversion to
fatty acids within the liver. A typical fed state contribution to total liver fat has been
estimated to be 23% [57], whilst fasted contributions are substantially lower at 4.7%.
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However, individuals with NAFLD experience elevated DNL contributions to liver
fat in the fasted state (26% [14]) indicating a chronic up-regulation of this pathway.
The largest contribution to hepatic lipid stores is from the lipolysis of visceral and
subcutaneous adipose tissue, measured at 61.7% and 81.7% for healthy subjects in
the fed and fasted states respectively [14].
Central to the debate on the pathology of hepatic steatosis is the role of insulin re-
sistance. Insulin resistance in adipose tissue results in a failure to suppress lipolysis
and therefore higher levels of non-esterified fatty acids (NEFA) in the blood. As the
largest contributor to liver fat is NEFA, it is easy to see why insulin resistance may
lead to a higher hepatic TAG concentration. Conversely, increased lipid deposits in
the liver can cause insulin resistance through impaired liver function [49]. In general,
fat stored in tissues other than adipose has the potential to cause insulin resistance
through impaired function of these other tissues (notable examples are pancreatic
insulin-secreting beta cells, and skeletal muscle). This interrelation between lipid
metabolism and insulin resistance leads us to consider both lipid and carbohydrate
metabolism in the study of hepatic steatosis.
Many mathematical models concerning metabolism already exist, focusing on a range
of scales and areas pertinent to the study of hepatic lipid metabolism. Stable isotope
tracers have been used in conjunction with compartmental modelling to elucidate
the kinetics of apoB (a key structural protein in lipoproteins) and triglyceride across
VLDL subfractions simultaneously. Adiels’ model [2] has proven to be a particularly
useful tool in determining how physiological features impact VLDL size and dyslipi-
demia [4, 3, 39, 38]. A more in-depth model of VLDL assembly has been proposed
by Shorten and Upreti [50] in which the lipid composition of secreted VLDLs can be
determined from uptake of individual free fatty acids after elongation and desatura-
tion by liver enzymes. Another area of mathematical modelling is the hepatic uptake
and metabolism of lipoproteins, and the competition between subclasses within this
process [46, 58].
Initial modelling of in vivo metabolic systems focused on predicting the glucose and
insulin response to carbohydrate loads, with applications in the study of diabetes.
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Bergman’s minimal model [7] provided a method to ascertain insulin sensitivity and
glucose effectiveness in response to oral glucose tolerance tests (OGTT). Since then,
many models have expanded [13] and extended [54] this to other physiological sit-
uations. Increased understanding of insulin production has led to enhanced models
of secretion [42], and the use of modelling combined with stable isotopes tracers has
allowed for a better understanding of glucose rate of appearance in the blood, inde-
pendent of other processes [40].
Several models exist for the study of metabolism in individual tissues, e.g. in skeletal
muscle [36, 12], in adipose tissue [33, 31] and in the brain [45]. These models tend
to rely on flux balance analysis to obtain information about large scale metabolic
networks at steady state, and are thus not always suitable for studying postprandial
dynamics. Previous work on whole body models of metabolism has included some,
but not all, of the features we would like to include in a model focused on hepatic
lipid metabolism. Jelic et al [27] produce a model focusing on NEFA dynamics which,
from prescribed insulin profiles of an OGTT, accurately predict true NEFA concen-
trations. Man et al [41] consider muscle and adipose tissue together as peripheral
tissues, along with liver and pancreatic beta cells, but do not include a fat element to
their model. In a PhD thesis on the subject, Kim [31] produces a detailed model of
the metabolic networks in multiple tissues and organs through flux balance analysis.
Here, the focus is on the fasted state, with applications to exercise, not the long term
dynamics.
Our aim in this paper is to develop a mathematical model capable of simulating
changes in the concentration of hepatic fat. Thus our model must be capable of re-
producing the metabolic response to mixed meals in both fed and fasted conditions.
From our discussion of the pathways and metabolic abnormalities which may lead
to hepatic steatosis, we take an integrated approach modelling other key tissues and
metabolites in addition to liver triglyceride. These do not need to be modelled pre-
cisely, but rather retain enough information to allow flexibility in model assessment.
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2. Mathematical modelling
In the derivation below we introduce variables corresponding to the evo-
lution of various species over time. We use G to represent glucose, P for
glucose-6-phosphate, R for pyruvate, Y for glucogen, A for FFA/NEFA, L
for glycerol, and T (and S) for TAG concentrations. We use subscripts to
distinguish between the several tissue types that we are concerned with:
namely m for muscle, L for liver, A for adipose tissue and B for blood
plasma, though in this last case, we use additional subscripts to make a
distinction between, exogeneous and endogenous TAG, for example. Due
to the large number of parameters used, it is impossible to have a con-
sistent naming policy here, we have used combinations of k∗, v∗, α∗ with
subscripts that contain some information on the process being modelled.
The kinetic equations are generally derived using the law of mass action,
with complicating factors introduced where this simplest approach fails
and a more complicated description is required. For example, Michaelis-
Menten rate kinetics [43] are used in some places, where the effects of
other species acting as catalysts or inhibitors is significant. In a couple
of places, this is extended further, to rates determined by Hill functions
with exponent two. Whilst a few transport processes occur by passive
diffusion, in which case the flux is simply described by the concentration
gradient, many transport processes are active and predominantly in one
direction, so more complex descriptions are required. These are described
on a case-by-case basis.
2.1. Compartmentalisation
Since our aim is to understand the biochemical complexity of the reaction and trans-
port processes occurring in the human body, we minimise the structural information
in our model. We propose a “lumped” model using a single concentration as rep-
resentative of each chemical species in each tissue. We split the model into four
compartments, that of liver, adipose tissue, skeletal muscle, and blood plasma, as the
transport mechanism between the other three compartments. The roles of some other
organs and tissues are discussed later in the derivation.
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The role of the liver in regulating the levels of metabolites available for other tissues
means that any study of metabolism in the liver necessarily involves other tissues
having a substantial turnover of these metabolites. Transport between the tissues is
mediated through the blood plasma, since this involves all other tissues it is the most
complicated to derive, and we leave the derivation of a governing equation for the
blood plasma till last. The body’s primary energy store adipose tissue, and skeletal
muscle each have a substantial impact on metabolism, comprising approximately 20%
and 40% respectively of the body by volume (in a healthy individual).
To account for the differences in the volume of compartments, we scale each differ-
ential equation by the size of the compartment which it concerns. The quantities
αB, αL, αM , and αA denote the volumes of blood, liver, skeletal muscle, and adipose
tissue respectively. The full list of variables included in the model are summarised in
Table 1. The overall scheme of reactions and transport is illustrated in Figure 1.
Note, throughout the model derivation, we assume a TAG molecule breaks down to
form 3 FFAs, and similarly, 3 FFAs are required to form a TAG molecule.
Liver Muscle
Glucose GL Glucose GM
Glycogen YL Glycogen YM
G-6-P PL G-6-P PM
Pyruvate RL Pyruvate RM
FFA AL FFA AM
TAG Storage Pool TL TAG TM
TAG Secretory Pool SL Notional AMP P
Plasma Adipose
Glucose GB Glucose GA
NEFA ANB FFA AA
Endogenous TAG TLB TAG TA
Exogenous TAG TCB Glycerol LA
Insulin I
Table 1: Complete list of variables used in the model.
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Figure 1: Model Diagram: at the top we show dietary input of glucose and TAG, on the right
are liver components, on the left muscle, and at the bottom, adipose tissue. In the centre are
plasma compartments. In addition to the variable names and descriptions, we include
a parameter associated with each flux, plus and minus superscripts represent insulin
stimulated and insulin inhibited pathways (respectively).
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2.2. Dietary inputs
Our model receives inputs from the gut from the dietary substrates TAG, glucose and
fructose. We denote these by ST (t), SG(t), SF (t), respectively. The latter two are the
only forms of carbohydrate we consider, the reason for separating these two is that
the former elicits an insulin response whilst the latter does not. Sugars and fats enter
the metabolic system in different ways. Glucose and fructose are both transported
from the intestinal tract into the hepatic portal vein, from which they are eventually
taken up by the liver. For simplicity, we choose not to explicitly include the glucose
concentration in the hepatic portal vein, instead having a function adding dietary glu-
cose directly to the liver glucose pool. Similarly for fructose, but once inside the liver
it is converted (via several steps) to an intermediate in the glycolytic/gluconeogenic
pathway. Fructose enters the pathway in the form of fructose-6-phosphate, an inter-
mediate in the conversion of G-6-P to pyruvate. Since we aim to keep the number of
variables to a minimum, we make the simplification that fructose enters the system as
pyruvate in the liver. This simplification is valid, since fructose will almost certainly
be ingested along side glucose, and therefore the glycolytic flux will be higher than
that of gluconeogenic flux, forcing the metabolites towards pyruvate. Fatty acids dif-
fer in that they are packed into chylomicrons in the form of TAG and released through
the lymphatic system before entering the blood stream. Hence, in our model, dietary
fat enters via the plasma chylomicron TAG pool.
Analysis of glucose concentrations in plasma from experimental data [18] suggests the
following functions are appropriate for our diet function
SG(t) = αGte
−t/βG , SF (t) = αF te
−t/βF , ST (t) = αT te
−t/βT . (1)
We assume similar shapes for the profiles of glucose, fructose and TAG,
albeit with different parameters to reflect the different mechanisms by
which these substrates are processed by the human body. Here the half-life
of the absorption is approximately β ln 2, and the total amount of each quantity taken
up is αβ2.
2.3. Hormonal regulation
Our model must be capable of simulating human metabolism in both fed and fasted
states. The primary regulatory hormone involved in switching between the dominant
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active metabolic pathways in these two states is insulin. We ignore the effects of
the counter-regulatory hormone glucagon for the moment as, in general, the two hor-
mones have opposite effects; higher concentrations of insulin are seen when glucagon
is low, and low concentrations when glucagon is high. In reality this relationship is
more complicated, due to additional factors, such as glucagon stimulating the release
of insulin, and some ketogenic and lipogenic pathways being affected by glucagon
alone [37].
Glucose has the largest effect on the secretion of insulin, with amino acids, ketone
bodies, and FFA having a significantly smaller effect, which we ignore in our model.
Importantly, fructose does not elicit an insulin response, which is why we have treated
it separately.
Experimental data of Harrison et al [22] suggests that insulin release (as a function of
plasma glucose levels) takes the form of a sigmoidal function plus a basal secretion rate
independent of glucose. Further experimental evidence [29] suggests the pancreatic
beta cells have a Gaussian distribution of thresholds at which they release stored
insulin. This relationship implies that the rate at which stored insulin is released is
the integral of the Gaussian distribution, giving the error function [1] (in agreement
with the sigmoidal shape predicted). Therefore we model the change in insulin by
the sum of an error function and a basal secretion rate (k11), less a degradation term
proportional to the amount of insulin, hence
d I
d t︸︷︷︸
rate of change of
plasma insulin
= k11 + k22 erf
(
GB − v
cc
)
︸ ︷︷ ︸
Insulin production
-glucose stimuated
− kdI,︸︷︷︸
insulin
degradation
(2)
where v is the mean threshold value at which pancreatic beta cells release insulin.
2.4. Liver
2.4.1. Liver carbohydrate
Whilst the GLUT2 transporters present in the liver allow passive diffusion of glucose
between plasma and liver, experimental data suggests this does not operate close to
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equilibrium (i.e Fick’s laws may not apply). We assume that plasma glucose (GB)
enters the liver at a rate proportional to plasma concentration with rate constant kgl2;
similarly, glucose diffuses from the liver to the blood at a rate proportional to the
liver concentration (GL) with rate constant kgl.
To prevent a state of hyperglycemia, the liver traps large amounts of glucose in the
form of glucose-6-phosphate (G-6-P). In the liver, this is handled by two enzymes,
hexokinase and glucokinase. We assume Michaelis-Menten kinetic forms for these
functions with rates vLH , vLG and Michaelis-Menten constants kLH , kLG respectively.
There is added complexity in that hexokinase is strongly inhibited by its product,
G-6-P (PL) via a noncompetitive inhibition with flux control coefficient krep. The en-
zyme glucose-6-phosphatase reverses this process and is necessary for glucose release
in fasted conditions. We assume this occurs at a rate proportional to the concentra-
tion of G-6-P, with rate constant k6l.
Including the diet function, SG(t), the equation for liver glucose is
αL
dGL
d t︸ ︷︷ ︸
rate of change
of liver glucose
= SG(t)︸ ︷︷ ︸
input
from diet
− kglGL︸ ︷︷ ︸
glucose flux
to plasma
from liver
+ kgl2GB︸ ︷︷ ︸
glucose flux
from plasma
to liver
−
vLGGL
kLG +GL︸ ︷︷ ︸
conversion of
glucose to G-6-P
by glucokinase
−
vLHGL
kLH +GL
(
1
1 + krepPL
)
︸ ︷︷ ︸
conversion of
glucose to G-6-P
by hexokinase
+ k6lPL.︸ ︷︷ ︸
conversion
of G6P to
liver glucose
(3)
During high insulin conditions the liver stores glucose in the form of glycogen (glyco-
genesis) for future use, and breaks down glycogen to glucose (glycogenolysis) dur-
ing periods of low insulin corresponding to low plasma glucose levels. As in the
other mechanisms, glucose must first be converted to G-6-P, before being further
metabolised to glycogen, we do not consider any intermediary steps. These glycogen-
esis/glycogenolysis pathways require a little more thought to model, as the liver has
a finite glycogen storage capacity, which it will usually meet daily.
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We require glycogenesis to be roughly constant, until the liver is approaching its
maximum storage capacity, at which time the uptake rates should reduce to zero.
Defining the maximum glycogen store of the liver as lmax and introducing a small
parameter c0, we modify the glycogen synthesis by the smoothed step function
1
2
(1+
tanh ((lmax − YL)/c0)), where c0 represents the width of the range of glycogen values
over which uptake drops to zero.
Similarly we require glycogenolysis to be roughly constant, until the liver has almost
depleted its glycogen reserves at which point the release rate decreases continuously
to zero. We therefore adjust the release term by the factor YL/(YL + y0), where y0 is
another small parameter, representing the range of YL over which the release drops
to zero as the glycogen store is depleted.
The actual rate of glycogen synthesis is stimulated by insulin, and is proportional to
the concentration of the substrate available. We assign the rate kyl to this process.
In our model the most immediate substrate is G-6-P. Degradation of glycogen is
stimulated by glucagon, but since we consider only insulin in this model, we take the
pathway to be insulin-inhibited, with rate constants βL, kdl. The equation to describe
glycogen concentration in the liver is
αL
dYL
d t︸ ︷︷ ︸
rate of change
of liver
glycogen
= 1
2
kylIPL
(
1 + tanh
(
lmax − YL
c0
))
︸ ︷︷ ︸
conversion of G-6-P
to glycogen in the liver
-insulin-stimulated
−
βL
1 + kdlI
(
YL
YL + y0
)
.︸ ︷︷ ︸
release of liver glycogen
& conversion to G-6-P
-insulin-inhibited
(4)
Glucose-6-phosphate is involved in many pathways, here it is also considered as the
only intermediate between glucose and pyruvate in the glycolytic and gluconeogenic
pathways. In general, the glycolytic pathway can be thought of as insulin-stimulated,
and the gluconeogenic pathway insulin-inhibited. For the sake of simplicity, we assume
the rate of conversion of G-6-P to pyruvate is proportional to the insulin concentra-
tion and the concentration of the substrate G-6-P, and depends on the rate parameter
kp. Conversely, conversion of pyruvate to G-6-P is proportional to the concentration
of pyruvate, at an insulin inhibited rate, described by parameters β6 and kp6.
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We also take into account the glycerol dynamics dictated by breakdown of triglyc-
eride in adipose tissue (discussed in section 2.6). For now, we recognise that the
liver takes up glycerol as a gluconeogenic precursor, and under fasting conditions it
is metabolised within the liver to G-6-P. Intermediate glycerol concentrations in the
plasma are ignored, thus uptake of G-6-P is modelled as being from adipose glycerol
(LA), at rate kgp. Therefore,
αL
dPL
d t︸ ︷︷ ︸
rate of change
of G-6-P in
the liver
= −1
2
kylIPL
(
1 + tanh
(
lmax − YL
c0
))
︸ ︷︷ ︸
conversion of G-6-P
to glycogen in the liver
-insulin-stimulated
+
βL
1 + kdlI
(
YL
YL + y0
)
︸ ︷︷ ︸
release of liver glycogen
& conversion to G-6-P
-insulin-inhibited
+
β6RL
1 + kp6I︸ ︷︷ ︸
gluconeogenesis
Pyr 7→G-6-P
in liver
+
vLGGL
kLG +GL︸ ︷︷ ︸
conversion of
glucose to G-6-P
by glucokinase
+
vLHGL
kLH +GL
(
1
1 + krepPL
)
︸ ︷︷ ︸
conversion of
glucose to G-6-P
by hexokinase
− kpIPL︸ ︷︷ ︸
conversion
of G-6-P to
pyruvate
− k6lPL︸ ︷︷ ︸
conversion
of G-6-P to
liver glucose
+ kgpLA.︸ ︷︷ ︸
adipose glycerol
7→Liver G-6-P
transport
(5)
Pyruvate kinetics in the liver (RL) are more complex. In addition to the glycolytic
flux (k6l) and gluconeogenic flux (β6, kp6) already described, we take into account
de novo Lipogenesis, lactate uptake (from the Cori cycle), and glycerol return from
hydrolysis of adipose triglyceride.
Under anaerobic conditions, and following a meal, glucose is the primary fuel oxidised
in skeletal muscle, pyruvate cannot be fully oxidised, and lactate is produced. This
is released by skeletal muscle and taken up by the liver where it is converted back to
pyruvate. To keep the number of variables in the model to a minimum, we choose
to ignore the concentrations of lactate in muscle, plasma, and liver, and instead con-
sider muscle pyruvate to be directly transported to liver pyruvate (rate parameter
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kpp). Additionally, red blood cells produce a constant amount of lactate, which is
returned to the liver at rate µb.
Whilst de novo lipogenesis (DNL) involves several reactions, the only metabolites in
our model are pyruvate and the end product, FFA. We therefore choose our DNL
term to convert liver pyruvate directly to FFA. DNL is stimulated by insulin, and is
substrate-dependent, so initially we have DNL occurring at a rate kal proportional to
both insulin and pyruvate concentration (RL). The complete equation for pyruvate
kinetics in the liver is
αL
dRL
d t︸ ︷︷ ︸
rate of
change of
liver pyruvate
= kppRM︸ ︷︷ ︸
transport from
muscle to liver
(as lactate)
+ kpIPL︸ ︷︷ ︸
conversion
of G-6-P to
pyruvate
−
β6RL
1 + kp6I︸ ︷︷ ︸
gluconeogenesis
Pyr 7→G-6-P
in liver
− kalIRL︸ ︷︷ ︸
de novo
lipogenesis
Pyr 7→FFA
+ µb.︸︷︷︸
from
RBC
lactate
(6)
2.4.2. Liver lipid
We model fatty acid metabolism in the liver by considering three compartments, a
TAG storage pool (TL), a TAG secretory pool (SL), and an intermediate FFA pool
(AL). Plasma NEFA, lipoprotein remnants and hepatic DNL contribute to the in-
termediate FFA pool as previously described. The number of particles secreted, and
therefore the amount of FFA entering the immediate secretory pathway is modelled
as a saturating function of the concentration AL, with rate parameters v6, k6. Alter-
natively, intermediate FFA can be stored in the cytosol of hepatocytes. We assume
this process also saturates, with associated parameters, v8, k8. Beta-oxidation of fatty
acids has been shown to decrease in response to insulin [60], so we assume a loss of
FFA proportional to the amount of FFA at rate k7, and at an insulin-inhibited rate k5.
DNL adds to liver fatty acids at rate kal as previously described. Thus, the equation
for hepatic FFA is
αL
dAL
d t︸ ︷︷ ︸
rate of
change of
FFA in liver
= 3kclTCB︸ ︷︷ ︸
uptake of
exogenous plasma
TAG into liver FFA
+ kblANB︸ ︷︷ ︸
FFA transport
from plasma
to liver
+ 3krTLB︸ ︷︷ ︸
from
plasma TAG
(endogenous)
+ kalIRL︸ ︷︷ ︸
de novo
lipogenesis
Pyr 7→FFA
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+
3v10TL
k10 + TL︸ ︷︷ ︸
TAG storage
conversion
to FFA
−
3v6AL
k6 + AL︸ ︷︷ ︸
Liver FFA
input to TAG
secretary pool
−
3v8AL
k8 + AL︸ ︷︷ ︸
FFA
conversion to
TAG storage
−
k7AL
1 + k5I
.︸ ︷︷ ︸
β-oxidation
of FFA
(7)
TAG transferred to the secretory pool is released into plasma lipoproteins at a rate
proportional to the amount stored, therefore
αL
dSL
d t︸ ︷︷ ︸
rate of change
of TAG secretary
pool in liver
=
v6AL
k6 + AL︸ ︷︷ ︸
Liver FFA
input to TAG
secretary pool
− k9aSL.︸ ︷︷ ︸
export of TAG
from secretary
pool to plasma
(8)
The bulk addition of cytosolic stored TAG depends on the amount of TAG stored
and on hormonal regulation. Experimental evidence of Adiels et al [3] suggests that
the release of TAG is a saturating function of liver fat with rate parameters v9, k9.
Insulin’s effect on VLDL metabolism is to down-regulate the quantity of VLDL1
secreted, and up-regulate the quantity of VLDL2 secreted [4]. We let the term F (I)
denote the fraction of VLDL2 which is further lipidated to form the larger VLDL1
particles. Thus the equation for hepatic cytosolic TAG is
αL
dTL
d t︸ ︷︷ ︸
rate of change of
TAG storage
pool in liver
=
v8AL
k8 + AL︸ ︷︷ ︸
FFA
conversion
to TAG
− F (I)
v9TL
k9 + TL︸ ︷︷ ︸
release
of TAG into
plasma
−
v10TL
k10 + TL
.︸ ︷︷ ︸
TAG
conversion
to FFA
(9)
The choice of F (I) is detailed in the parameter estimation section, we assume F (I)
takes the form
F (I) = k12 tanh
(
v12 − I
k13
)
+ k14. (10)
Note that since k12 < k14 (see data in Table 3), this effect is not large, as
shown by the data of Søndergaard et al. [52].
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2.5. Skeletal muscle
2.5.1. Skeletal muscle carbohydrate
The storage and use of glucose in skeletal muscle is based on the same mechanisms
as in the liver, but with some fundamental differences, and different values for equiv-
alent parameters. The concentration of glucose-6-phosphatase (the enzyme used in
catalysing G-6-P to glucose) in skeletal muscle is incredibly low, and hence, we ig-
nore this reverse pathway. Another enzyme found in low concentrations in skeletal
muscle is pyruvate carboxylase, the first enzyme needed for gluconeogenesis from the
precursor pyruvate. Hence, we ignore the conversion of pyruvate to G-6-P.
Diffusion of glucose between plasma and tissue also differs, with the addition of
GLUT4 transporters present in skeletal muscle. We assume the number of GLUT4
transporters increases in proportion to the concentration of insulin. Thus the perme-
ability of the surface can be thought of as the combination of GLUT1 transporters
(represented by the rate kg) and of the GLUT4 transporters (represented by the rate
kgiI). Again, experimental evidence suggests that this diffusion acts far from equilib-
rium, so exchange from blood to muscle occurs at rate different from that of muscle
to blood at rate kgm2.
Unlike the liver, skeletal muscle contains no glucokinase, so phosphorylation is con-
strained to hexokinase only. We assume the same form for muscle hexokinase activity
(and G-6-P inhibition) as in the liver, here the associated constants are vMH , kMH ,
and krep. Thus the equation describing the evolution of glucose in skeletal muscle is
αM
dGM
d t︸ ︷︷ ︸
rate of change
of glucose
in muscle
= (1 + kgiI)(kgmGB − kgm2GM)︸ ︷︷ ︸
glucose transport
between plasma and muscle
-insulin stimulated
−
vMHGM
kMH +GM
(
1
1 + krepPM
)
.︸ ︷︷ ︸
conversion of glucose to G-6-P
by hexokinase
-inhibited by G-6-P
(11)
Glycogen storage and release in skeletal muscle operates in the same way as in the
liver, albeit with different parameters; hence we define the glycogen synthesis rate by
kym, and have degradation parameters βm, kdyI, with a maximum glycogen concen-
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tration of mmax. The equation for muscle glycogen is thus
αM
dYM
d t︸ ︷︷ ︸
rate of
change of
muscle glycogen
=
1
2
kymIPM
(
1 + tanh
(
mmax − YM
c0
))
︸ ︷︷ ︸
conversion of G-6-P to glycogen
in muscle
-stimulated by insulin
−
βm
1 + kdyI
(
YM
YM + y0
)
.︸ ︷︷ ︸
conversion of glycogen
to G-6-P in muscle
-insulin-inhibited
(12)
The glucose-6-phosphate concentration in skeletal muscle follows from the fluxes and
assumptions detailed above; however, the glycolytic flux out of G-6-P in skeletal
muscle occurs at a different rate to the liver, here the rate is taken to be k6p, hence
αM
dPM
d t︸ ︷︷ ︸
rate of
change of
muscle G-6-P
=
vMHGM
kMH +GM
(
1
1 + krepPM
)
︸ ︷︷ ︸
conversion of glucose to G-6-P
by hexokinase
-inhibited by G-6-P
−
1
2
kymIPM ·
(
1 + tanh
(
mmax − YM
c0
))
︸ ︷︷ ︸
conversion of G-6-P to glycogen
in muscle
-stimulated by insulin
+
βm
1 + kdyI
(
YM
YM + y0
)
︸ ︷︷ ︸
conversion of glycogen
to G-6-P in muscle
-insulin-inhibited
− k6pIPM .︸ ︷︷ ︸
glycolysis
G-6-P7→Pyr
in muscle
(13)
The pyruvate concentration in skeletal muscle is dictated by three components: sub-
strate entering through the glycolytic pathway (k6p), pyruvate release for uptake by
the liver (as lactate with rate parameter kpp), and consumption by skeletal muscle.
Carbohydrate oxidation in skeletal muscle is covered in detail in section 2.5.3; here
we have modelled it by the term µ3RMIP , thus the equation for muscle pyruvate is
αM
dRM
d t︸ ︷︷ ︸
rate of
change of
muscle pyruvate
= k6pIPM︸ ︷︷ ︸
glycolysis
G-6-P7→Pyr
in muscle
− kppRM︸ ︷︷ ︸
transport from
muscle to liver
(as lactate)
− µ3RMIP.︸ ︷︷ ︸
CHO oxidation
-insulin-stimulated
(AMP7→ATP)
(14)
2.5.2. Skeletal muscle lipid
For fat metabolism in skeletal muscle, we are concerned only with a TAG storage pool
and a FFA pool. The FFA pool is contributed to by chylomicron TAG, LP TAG and
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NEFA, with fluxes proportional to concentration at rates kcm, kt and kbm respectively.
Skeletal muscle stores FFA in the form of TAG at the insulin-dependent rate ms, and
releases TAG for energy when required. For simplicity, we assume that the breakdown
of TAG occurs at a constant rate, me, thereby always ensuring an adequate energy
supply. FFA oxidation is dictated by the term µ3RMIP , as discussed in section 2.5.3.
The equations for FFA and TAG in skeletal muscle are
αM
dAM
d t︸ ︷︷ ︸
rate of
change of
FFA in muscle
= − 3msIAM︸ ︷︷ ︸
FFA 7→TAG
in muscle
-insulin-stimulated
+ 3me︸︷︷︸
TAG7→FFA
in muscle
-constant
+ 3kcmTCB︸ ︷︷ ︸
uptake of plasma
TAG (exogenous)
into muscle FFA
+ kbmANB︸ ︷︷ ︸
FFA uptake
from plasma
into muscle
+ 3ktTLB︸ ︷︷ ︸
uptake of plasma
TAG (endogenous)
into muscle FFA
− µ4AMP,︸ ︷︷ ︸
FFA
oxidation
(AMP7→ATP)
(15)
αM
dTM
d t︸ ︷︷ ︸
rate of
change of
muscle TAG
= msIAM︸ ︷︷ ︸
FFA 7→TAG
in muscle
-insulin-stimulated
− me.︸︷︷︸
TAG7→FFA
in muscle
-constant
(16)
2.5.3. Skeletal muscle substrate oxidation
Skeletal muscle oxidation patterns demonstrate an ability to switch fuel choice from
mostly fatty acids in the fasted state, to predominantly glucose in the fed state,
facilitating the disposal of a carbohydrate load. We introduce the equation describing
P , a notional AMP concentration. Energy expenditure is assumed to be constant,
thus AMP is created at a constant rate µamp. AMP is converted back to ATP via
fuel oxidation. Fatty acid oxidation contributes to the replenishment of AMP to ATP
at a rate proportional to the concentration of available free fatty acids, AM and to
the amount of AMP that needs replenishing (P ) with the constant of proportionality
being µ4. In a similar way, carbohydrates also contribute to reducing P , but with
the additional influence of insulin in promoting the use of carbohydrate as a fuel
source. For simplicity we assume insulin exerts this effect linearly. Again, oxidation is
proportional to the amount of AMP that needs replenishing (P ) and to the availability
of substrates, in this case, pyruvate (RM), as the last metabolite modelled in the
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glycolytic pathway. Hence P is governed by
dP
d t︸︷︷︸
rate of
change of
AMP in muscle
= µamp︸︷︷︸
Production of
AMP from ATP
by exercise
− µ4AMP︸ ︷︷ ︸
FFA
oxidation
AMP7→ATP
− µ3RMIP.︸ ︷︷ ︸
CHO oxidation
-insulin-stimulated
AMP7→ATP
(17)
2.6. Adipose tissue
Whilst we only model FFA and TAG in the lipid storage dynamics of skeletal muscle
and the liver, adipose tissue requires the consideration of additional species. TAG is
formed from a combination of a glycerol-3-phosphate backbone (a product of glycol-
ysis) and three fatty acids. When TAG is hydrolysed by lipases in adipose tissue, the
backbone is released in the form of glycerol alone, i.e no phosphate group is attached.
Since adipose tissue lacks the enzyme required to convert glycerol to G-3-P (glycerol
kinase), glycerol leaves the cell, and a new G-3-P must be synthesised. Two G-3-P
molecules can be synthesised from one glucose molecule. The glycerol leaving adipose
tissues is returned to the liver where it can be used as a gluconeogenic precursor.
We do not model the concentration of G-3-P, instead we consider these processes to
involve only glucose, FFA, TAG and glycerol.
TAG is synthesised from available free fatty acids (AA), and a glycerol backbone
(synthesised from glucose GA). This process is stimulated by insulin at rate kaa.
Adipose TAG is broken down to FFA for release as NEFA in fasted conditions. The
main enzyme responsible for this (hormone sensitive lipase) is inhibited by insulin.
Note, in parameterising this process to data, we required inhibition to be proportional
to insulin squared. Importantly, since the concentration of adipose TAG in a healthy
person would be well above any substrate saturating level, we model the breakdown
and release of TAG with no substrate dependence. Thus TAG breakdown to FFA
and immediate release into NEFA is modelled by the rate βf , and inhibited by insulin
with parameter kft. The equation for adipose TAG is thus
αA
dTA
d t︸ ︷︷ ︸
rate of
change of
adipose TAG
= kaaIAAGA︸ ︷︷ ︸
TAG production
from FFA and
glucose/glycerol
−
βf
1 + kftI2
.︸ ︷︷ ︸
Release of adipose
TAG to plasma FFA
-insulin-inhibited
(18)
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Adipose tissue takes up TAG from chylomicrons, and from lipoproteins released from
the liver. LPL, which is responsible for removing this TAG from the lipoproteins, acts
at a basal rate in fasted conditions, but its activity increases in response to insulin.
Note, LPL activity is only up-regulated by insulin in adipose tissue, it is unchanged
or decreased in skeletal muscle [17]. We therefore model TAG uptake as proportional
to the concentrations of the respective lipoproteins, and the sum of basal (ka, kba)
and insulin-stimulated rates (kai). Note, the action of LPL on the lipoproteins breaks
down this TAG to FFA as it crosses the tissue lining, thus lipoprotein derived TAG
adds to the adipose FFA pool (AA), not the TAG pool. This process is inherently
’leaky’ and thus a proportion klp is transferred to the plasma. The conversion of FFA
to TAG is modelled as proportional to concentrations of fatty acids, glucose, and to
insulin as previously described (with rate parameter kaa). Additionally, adipose can
take up NEFA from the pool released by adipose TAG. This takes place at rate kna
proportional to the NEFA concentration. Thus the equation for adipose FFA is
αA
dAA
d t︸ ︷︷ ︸
rate of
change of
adpipose FFA
= − 3kaaIAAGA︸ ︷︷ ︸
TAG production
from FFA and
glucose/glycerol
+ 3ka(1 + kaiI)(1− klp)TCB︸ ︷︷ ︸
uptake of plasma
TAG (exogenous)
by adipose tissue
+ 3kbaTLB︸ ︷︷ ︸
uptake of plasma
TAG (endogenous)
into Adipose FFA
+ knaANB.︸ ︷︷ ︸
uptake of
plasma FFA
into adipose FFA
(19)
The glycerol backbone produced in the breakdown of TAG is released at the same rate
as adipose TAG is broken down, the associated rate parameters being βf , kft. The
glycerol released into the plasma is taken up by the liver. We do not explicitly model
the concentration of glycerol in the plasma, instead, we model the direct uptake
of adipose glycerol to the liver at a rate kgp proportional to the adipose glycerol
concentration LA, hence
αA
dLA
d t︸ ︷︷ ︸
rate of
change of
adipose glycerol
=
βf
1 + kftI2︸ ︷︷ ︸
Release of adipose TAG
to plasma FFA-insulin-inhibited
also releasing glycerol
− kgpLA.︸ ︷︷ ︸
adipose glycerol
7→ Liver G-6-P
transport
(20)
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The major supply of G-3-P necessary for the storage of FFA as TAG is sourced from
plasma glucose and metabolised to G-3-P within adipose tissue. Rather than model
every metabolite in the glycolytic pathway leading to G-3-P, we consider adipose
glucose as a proxy for G-3-P. Taking into account GLUT1 (dBA), and GLUT4 (kga)
transporters (in a similar manner as to skeletal muscle), we allow for the diffusion
of glucose between plasma (GB) and adipose glucose (GA). As previously described,
this glucose is metabolised to G-3-P for esterification with FFA at a rate kaa, hence
αA
dGA
d t︸ ︷︷ ︸
rate of change
of glucose in
adipose tissue
= dBA(1 + kgaI)(GB −GA)︸ ︷︷ ︸
glucose transport
between plasma
and adipose tissue
− kaaIAAGA.︸ ︷︷ ︸
TAG production
from FFA and
glucose/glycerol
(21)
2.7. Plasma variables
The evolution of the plasma variables consist of fluxes between compartments already
described, as well as usage by other tissues. A short summary of terms is given below.
As previously discussed, dietary fat SF (t) adds to the chylomicron TAG pool, and is
taken up by skeletal muscle (kcm), adipose tissue (ka , kai) and liver (kcl), thus the
concentration TCB is given by
dTCB
d t︸ ︷︷ ︸
rate of change
of exogenous
TAG in plasma
= SF (t)︸ ︷︷ ︸
input
from
diet
− kcmTCB︸ ︷︷ ︸
uptake of plasma
TAG (exogenous)
into muscle FFA
− kclTCB︸ ︷︷ ︸
uptake of
exogenous plasma TAG
into liver FFA
−ka(1 + kaiI)TCB.︸ ︷︷ ︸
uptake of plasma
TAG (exogenous)
by adipose tissue
(22)
NEFA is released by adipose tissue (βa, kab), and taken up by the liver (kbl), adipose
tissue (kna), and by muscle (kbm). Additionally, the action of LPL on circulating
lipoproteins leaks fatty acids into the plasma at a rate klp proportional to the TAG
extracted.
dANB
d t︸ ︷︷ ︸
rate of
change of
plasma FFA
= − kbmANB︸ ︷︷ ︸
FFA uptake
from plasma
into muscle
− kblANB︸ ︷︷ ︸
FFA transport
from plasma
to liver
− knaANB︸ ︷︷ ︸
uptake of
plasma FFA
into adipose FFA
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+
3βf
1 + kftI2︸ ︷︷ ︸
Release of adipose TAG
to plasma FFA-insulin-inhibited
also releasing glycerol
+ 3kaklp(1 + kaiI)TCB.︸ ︷︷ ︸
adipose tissue uptake
of TAG from plasma
(exogenous)
(23)
Endogenously derived lipoprotein TAG (TLB) is secreted from the liver (v9,k9,k9a)
and taken up by skeletal muscle (kt) , adipose tissue (kba), and as remnant particles
by the liver (kr), hence
dTLB
d t︸ ︷︷ ︸
rate of change
of endogenous
plasma TAG
= F (I)
v9TL
k9 + TL︸ ︷︷ ︸
from
liver
TAG
+ k9aSL︸ ︷︷ ︸
export of TAG
from secretary
pool to plasma
− krTLB︸ ︷︷ ︸
taken up
by liver
as FFA
− ktTLB︸ ︷︷ ︸
uptake of plasma
TAG (endogenous)
into muscle FFA
− kbaTLB.︸ ︷︷ ︸
uptake of plasma
TAG (endogenous)
into Adipose FFA
(24)
Ebbert and Jensen [16] review the literature on free fatty acid metabolism
and the effects of high levels. They note that upto 50% of NEFA comes
from visceral fat, but do not comment on the effect of subcutaneous fats.
Whilst the work of Jensen et al. [28] provides a more detailed analysis of
FFA kinetics, their data is from dogs, not humans.
Plasma glucose diffuses between liver (kgl, kgl2), skeletal muscle (kg, kgi, kgm, kgm2)
and adipose (kga, dBA) as previously described. Plasma glucose can be used as a fuel
source by a number of organs/cells, the largest two consumers being the brain and
red blood cells. Since these consumers use glucose at an almost constant rate, we
introduce a term for the removal of glucose at constant rate µ1
dGB
d t︸ ︷︷ ︸
rate of
change of
plasma glucose
= kglGL︸ ︷︷ ︸
glucose flux
to plasma
from liver
− kgl2GB︸ ︷︷ ︸
glucose flux
from plasma
to liver
− (1 + kgiI)(kgmGB − kgm2GM)︸ ︷︷ ︸
glucose transport
between plasma and muscle
-insulin-stimulated
−dBA(1 + kgaI)(GB −GA)︸ ︷︷ ︸
glucose transport
between plasma
and adipose tissue
− µ1.︸︷︷︸
use of
glucose
as fuel
(25)
This completes the model.
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2.8. Summary
The variables and transport processes are summarised in Figure 1. We now summarise
the equations derived above.
d I
d t
= k11 + k22 erf
(
GB − v
cc
)
− kdI, (2)
αL
dGL
d t
= SG(t)− kglGL + kgl2GB −
vLGGL
kLG +GL
−
vLHGL
kLH +GL
(
1
1 + krepPL
)
+ k6lPL, (3)
αL
dYL
d t
= 1
2
kylIPL
(
1 + tanh
(
lmax − YL
c0
))
−
βL
1 + kdlI
(
YL
YL + y0
)
, (4)
αL
dPL
d t
= −1
2
kylIPL
(
1 + tanh
(
lmax − YL
c0
))
+
βL
1 + kdlI
(
YL
YL + y0
)
− kpIPL + kgpLA
+
β6RL
1 + kp6I
+
vLGGL
kLG +GL
+
vLHGL
kLH +GL
(
1
1 + krepPL
)
− k6lPL, (5)
αL
dRL
d t
= kppRM + kpIPL −
β6
1 + kp6I
RL − kalIRL + µb, (6)
αL
dAL
d t
= 3kclTCB + kblANB + 3krTLB + kalIRL −
3v6AL
k6 + AL
+
3v10TL
k10 + TL
−
3v8AL
k8 + AL
−
k7AL
1 + k5I
, (7)
αL
dSL
d t
=
v6AL
k6 + AL
− k9aSL, (8)
αL
dTL
d t
=
v8AL
k8 + AL
− F (I)
v9TL
k9 + TL
−
v10TL
k10 + TL
, (9)
αM
dGM
d t
= (1 + kgiI)(kgmGB − kgm2GM)−
vMHGM
kMH +GM
(
1
1 + krepPM
)
, (11)
αM
dYM
d t
=
1
2
kymIPM
(
1 + tanh
(
mmax − YM
c0
))
−
βm
1 + kdyI
(
YM
YM + y0
)
, (12)
αM
dPM
d t
=
vMHGM
kMH +GM
(
1
1 + krepPM
)
− kymIPM ·
1
2
(
1 + tanh
(
mmax − YM
c0
))
+
βm
1 + kdyI
(
YM
YM + y0
)
− k6pIPM , (13)
αM
dRM
d t
= k6pIPM − kppRM − µ3RMIP, (14)
αM
dAM
d t
= −3msIAM + 3me + 3kcmTCB + kbmANB + 3ktTLB − µ4AMP, (15)
αM
dTM
d t
= msIAM −me, (16)
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dP
d t
= µamp − µ4AMP − µ3RMIP, (17)
αA
dTA
d t
= kaaIAAGA −
βf
1 + kftI2
, (18)
αA
dAA
d t
= −3kaaIAAGA + 3ka(1 + kaiI)(1− klp)TCB + 3kbaTLB + knaANB, (19)
αA
dLA
d t
=
βf
1 + kftI2
− kgpLA, (20)
αA
dGA
d t
= dBA(1 + kgaI)(GB −GA)− kaaIAAGA, (21)
dTCB
d t
= SF (t)− kcmTCB − kclTCB − ka(1 + kaiI)TCB, (22)
dANB
d t
= −kbmANB − kblANB − knaANB +
3βf
1 + kftI2
+ 3kaklp(1 + kaiI)TCB, (23)
dTLB
d t
= F (I)
v9TL
k9 + TL
+ k9aSL − krTLB − ktTLB − kbaTLB, (24)
dGB
d t
= kglGL − kgl2GB − (1 + kgiI)(kgmGB − kgm2GM) (25)
−dBA(1 + kgaI)(GB −GA)− µ1.
2.9. List of Parameters
Table 2 summarises the expected fasted steady-state values of all the system’s vari-
ables. The values used for the parameters, and source for these values are quoted in
Table 3. Following these tables, more detail is given on the derivations of a couple of
the parameter values which are more difficult to obtain (v9, kba, kbk).
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Description Variable Steady value Reference
Liver Glucose GL 8mmol/l [31]
Liver Glycogen YL 50mmol/l Healthy fasting liver conc.
Liver G-6-P PL 2.06mmol/l Model run to steady state.
Liver Pyruvate RL 0.37mmol/l [31]
Liver FFA AL 0.57mmol/l [31]
Liver TAG Storage Pool TL 40mmol/l Healthy fasting liver conc.
Liver TAG Secretory Pool SL 0.0149mmol/l Model run to steady state.
Muscle Glucose GM 0.5mmol/l [36]
Muscle Glycogen YM 20mmol/l Healthy fasting muscle conc.
Muscle G-6-P PM 0.133mmol/l [48]
Muscle Pyruvate RM 0.009mmol/l [36]
Muscle FFA AM 0.53mmol/l [36]
Muscle TAG TM 14.8mmol/l [36]
Plasma Glucose GB 5mmol/l [19]
Plasma Insulin I 60pmol/l [19]
Plasma NEFA ANB 0.5mmol/l [19]
Plasma Exogenous CM TAG TCB 0mmol/l [19]
Plasma Endogenous LP TAG TLB 1mmol/l [19]
Adipose Glucose GA 2.53mmol/l [56]
Adipose FFA AA 0.57mmol/l [31]
Adipose TAG TA 500mmol/l Healthy conc.
Adipose Glycerol LA 0.17mmol/l [25]
Table 2: Steady state concentrations.
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Table 3: Parameter values used in simulations.
Parameter Value Description Source
αA 15.6l Volume of adipose tissue A 70kg individual with a BMI of 21.5kg/m
2 (healthy), has an estimated
body fat of 20% (1994 National Health and Nutrition Examination Study).
Conversion to volume is obtained from an adipose tissue density of 0.9kg/l.
αB 5l Volume of blood [19].
αL 1.6l Volume of the liver [5].
αM 26.4l Volume of skeletal muscle A 70kg individual has an estimated 40% body weight in skeletal muscle.
Conversion to volume is obtained from an skeletal muscle tissue density of
1.06kg/l.
β6 31.6 Rate of liver DNL from pyruvate [31], [32].
βf 0.117mmol/min Adipose release of TAG to NEFA Approximated from data in Bickerton [8, 9].
βl 12l/min Liver glycogenolysis Approximations from considering data in Taylor [55], solving glycogenolysis
and glycogenesis rate equations simultaneously.
βm 82.5l/min Muscle glycogenolysis [31].
µamp 1.8 Notional AMP/ADP creation rate A typical energy expenditure of 10MJ/day is assumed [19]. 15% of this is
satisfied by protein consumption [19], and 2025 from brain usage, leaving
6475kj. Conversion for molar density and energy density gives 1.8.
µb 0.133mmol/min Lactate production by red blood cells [19].
µe 0.420mmol/min Muscle TAG breakdown to FFA Small, set to the fasting FFA oxidation rate.
µs 7.19× 106lmmol−1min−1 Muscle FFA esterification to TAG, Rate chosen such that the skeletal muscle FFA concentration is 0.57 mmol/l.
µ1 0.588mmol/min Plasma glucose usage Total rate is the sum of brain and red blood cell use. Brain usage of
plasma glucose is 0.458mmol/min (120g/day). Red blood cell usage 0.133
(25mg/min ) [19].
µ3 7.839× 107lmmol−1min−1 Muscle G-6-P usage Approximate glucose usage in periphery is 3.2MJ [19]. Rate takes into ac-
count G-6-P and insulin concentration, and FFA usage. Ratio of µ3 and µ4
determines usage.
µ4 100l/min Muscle FFA usage Approximate FFA usage in periphery is 6.1MJ [19]. Rate takes into account
muscle concentration, and glucose usage. Ratio of µ3 and µ4 determines
usage.
c0 0.1mmol/l Small parameters Chosen to be < O(0.01) of glycogen concentration
cc 2.5mmol/l Range of glucose concentrations over
which excess insulin secretion occurs
Obtained from a simple least squares data fit of experiments in [22] (Figure
1A).
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dBA 0.3 Adipose uptake of glucose Rate chosen such that the adipose glucose steady state concentration is
2.54mmol/l [56].
k10 0.625mmol/l Affinity for hydrolysis of TAG to secre-
tory pool
Arbitrary small parameter. Chosen to be < O(0.01) of TAG pool.
k11 48mmol/min Basal insulin secretion rate Obtained from a simple least squares data fit of experiments in [22] (Figure
1A).
k12 0.2 Increased fraction of VLDL1 secretion
by insulin
Simple least squares fitting of multiple data sets [3] [4] [39] [20].
k13 15mmol/l Rate at which insulin modifies the frac-
tion of VLDL1/VLDL2 secretion
See k12
k14 0.6 Basal VLDL1 secretion fraction See k12
k22 48mmol/min Excess insulin secretion rate due to
glucose stimulation
Obtained from a simple least squares data fit of experiments in [22] (Figure
1A).
k5 8.23× 107mmol−1 Flux control coefficient for insulin in-
hibition of FFA oxidation
Estimated from experiments in Westerbacka [60].
k6 0.3mmol/l Affinity for VLDL2 TAG secretion
through secretory pathway
Chosen to be < O(0.01) of FFA concentration
k6l 4l/min Liver glucose dephosphorylation rate [31]
k6p 6.56× 108l2mmol−1min−1 Muscle G-6-P to pyruvate conversion
rate
Chosen such that steady state concentration of muscle G-6-P is 0.13 mmol/l.
k7 0.759l/min Max rate of FFA oxidation For a liver TAG concentration of 45mmol/l at steady state, the oxidation
rate is set to maintain this. Parameter is adjusted for insulin inhibition by
fitting to experimental data in Westerbacka et al [60]. Note, we assume ketone
production is proportional to FFA oxidation.
k8 0.625mmol/l Affinity for esterification of FFA to
TAG
Small parameter chosen to be < O(0.1) of FFA concentration.
k9 43.583mmol/l Affinity of additional bulk lipidation See v9.
k9a 1l/min Release of VLDL from secretory path-
way
Set to unity.
ka 0.1497l/min Adipose FFA uptake of CM TAG (in-
sulin independent)
Turnover of chylomicron TAG is estimated to have a half life of 4.5min [21].
We use a 5 minute half life giving a total degradation rate of log 2/5 = 0.1386.
The liver takes up gives 4% of this [23]. Bickerton [8] shows adipose tissue
uptake 3 times more than skeletal muscle, therefore adipose uptake given by
72% of 0.1386.
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kaa 3.11× 105l2mmol−2min−1 Adipose FFA esterification to TAG Rate chosen such that the adipose FFA concentration is 0.57 mmol/l in the
steady state.
kai 2.08× 10
6mmol−1 Adipose FFA uptake of CM TAG (in-
sulin dependent)
Negligible compared to insulin independent take up.
kal 0.00002l
2mmol−1min−1 Pyruvate to ACoA conversion rate [31], [32].
kba 0.0104l/min Adipose uptake of endogenous LP
TAG
See description below
kbl 0.156l/min Liver uptake of plasma NEFA See description below
kbm 0.226l/min Muscle uptake of plasma NEFA See kbl, muscle 50% of (of 0.4510)
kcl 0.0075l/min Liver FFA Take-Up of chylomicron
TAG
See ka Rate given by 4% of 0.1386.
kcm 0.0449l/min Muscle FFA take up of chylomicron
TAG
See ka.Rate given by 24% of 0.1386.
kd 1.733× 10
8l/min Insulin degradation rate The half life of insulin is approximately 4 − 6 minutes[15]. The degradation
rate is calculated by (ln 2/half life). We use the lower bound of 4minutes.
kdl 3.5× 10
8l/mmol Liver glycogenolysis (insulin inhibited
rate)
See βl
kdy 4× 10
8mmol−1 Muscle glycogenolysis (insulin inhib-
ited rate)
See βm
kft 1.67× 10
14mmol−1 Adipose release of TAG to NEFA (in-
sulin inhibited rate)
Approximated from data in Bickerton [8, 9].
kga 1.67× 106mmol−1 Adipose uptake of glucose Rate chosen such that the adipose glucose steady state concentration is
2.54mmol/l [56].
kgi 2.632 × 10
7mmol−1 Approximated using data from Kelley
and Kraegen simultaneously [30, 35]
See kg
kgl 0.9277l/min Liver to blood glucose scalar In combination with kgl2 this confers steady state concentrations of liver
(8mmol/l) to blood (5mmol/l).
kgl2 0.396l/min Blood to liver glucose scalar In combination with kgl this confers steady state concentrations of liver
(8mmol/l) to blood (5mmol/l).
kgm 0.0380l/min Blood to muscle glucose scalar In combination with kgm2 this confers steady state concentrations of muscle
(0.5mmol/l) to blood (5mmol/l).
kgm2 0.0380l/min Muscle to blood glucose scalar In combination with kgm this confers steady state concentrations of muscle
(0.5mmol/l) to blood (5mmol/l).
kgp 0.311l/min Adipose glycerol return rate (to liver) Rate chosen such that the glycerol steady state concentration is 0.17mmol/l
[31]
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klp 0.25 Proportion of TAG released into the
plasma from the action of LPL.
Estimated
kLG 8.95mmol/l Glucokinase affinity coefficient [53]. Note, mouse data is used here.
kLH 0.0115mmol/l Hexokinase affinity coefficient [53]. Note, mouse data is used here.
kMH 8.95mmol/l Hexokinase affinity coefficient Same as kLG
kna 0.0697 Adipose uptake of plasma NEFA See kbl, adipose 15.45% of (of 0.4510)
kp 1.41× 107l2mmol−1min−1 Pyruvate to ACoA conversion rate [31, 32].
kp6 1.93× 108mmol−1 Liver pyruvate to G-6-P (insulin inhib-
ited)
Set such that gluconeogenesis and glycogenolysis produce equal quantities of
glucose [59].
kpp 0.5l/min Muscle Pyruvate return to liver pyru-
vate
Rate chosen such that the muscle pyruvate concentration is at the given steady
state.
kr 0.00058l/min Liver uptake of endogenous LP TAG See kba. Rate given by 4% of 0.0262.
krep 2.98l/mmol Hexokinase inhibition by G-6-P Simple least squares fitting of experiments in Crane [10].
kt 0.00348l/min Muscle uptake of endogenous LP TAG See kba. Rate given by 24% of 0.0262.
kyl 1.28× 10
6l2mmol−1min−1 Liver glycogenesis rate
kym 21.364l2mmol−1min−1 Muscle glycogenesis rate Average of estimates in Price [48] and Shulman [51] . Rate is adjusted for
glucose and insulin concentrations.
lmax 400mmol/l Maximum liver glycogen concentration [55].
mmax 100mmol/l Maximum muscle glycogen concentra-
tion
[19].
v 7mmol/l Required glucose concentration for half
maximal secretion of insulin
Obtained from a simple least squares data fit of experiments in [22] (Figure
1A).
v10 0.1l/min Max rate of hydrolysis of TAG to se-
cretory pool
Set to release the same quantity of TAG as secreted in nascent VLDL particles.
v12 40mmol/l Half maximal concentration for in-
sulin’s effect on switching the secretion
of lipoprotein fractions
See k12
v6 0.0158l/min Max rate of VLDL2 TAG secretion
through secretory pathway
See v9 description.
v8 0.333l/min Max rate of FFA esterification to TAG Comparatively very small, set to zero.
v9 0.0159l/min Maximum rate for the bulk lipidation
of VLDL
See additional parameter descriptions below.
vLG 14.3l/min Glucokinase max rate Estimated rate from Sreenan [53], Scaled for 1.6l liver volume. Note, mouse
data is used here.
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vLH 5.57l/min Hexokinase max rate Estimated rate from Sreenan [53], Scaled for 1.6l liver volume. Note, mouse
data is used here.
vMH 54.288l/min Hexokinase max rate See vLH . Scaled for 16.4l muscle volume.
y0 0.1mmol/l Small parameters Chosen to be < O(0.01) of glycogen concentration.
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v9 : Calculations from experimental data in [3, 2, 4]. For adjusted model parame-
ters, we calculate the average TAG per apoB molecule in VLDL2, 27.5mg kg−1day−1/
2.1mg kg−1day−1 = 13.095, multiply by total number of apoB secreted 9.2mgkg−1day−1,
which gives total TAG production excluding bulk lipidation from cytosolic TAG. Sub-
tracting 13.095×9.2 (average TAG per apoB multiplied by total apoB secretion), from
the VLDL1 TAG production, gives bulk lipidation. As a function of liver fat, we per-
form a simple non-linear least squares fit data to model equations; Vmax and KM
follow. Note 1g of TAG is taken to be equal to 1.14mmol in these calculations.
kba : Total rate of uptake of VLDL-TAG is set at 0.0262 to maintain a fasting plasma
TAG of 1mmol/l. Hodson et al [23] estimate 4% of TAG is taken up from the rem-
nant particles by the liver. Bickerton [8] estimates adipose tissue takes up 3 times
more TAG than skeletal muscle. Thus adipose tissue takes up 72% of 0.0262, whilst
skeletal muscle takes up 24% of 0.0262.
kbl : Plasma NEFA half life estimates vary from 30s to 3min [27], giving a total
degradation rate of 1.3863 to 0.2310min−1. We choose 0.4510min−1 calculated from
setting fasting NEFA to 0.5mmol/l. Jelic [26] estimates that 34.55% of plasma NEFA
is taken up by the liver. This value is in relatively good agreement with the work of
Nielsen et al. [44], who use measurements of palmitate uptake in leg muscle.
This completes the parameterisation of the model. In the next section (§3) we sum-
marise results of short-time simulations, before moving on to test the model against
independent data from longer timescale.
3. Results
A large body of experimental evidence is available for the profiles of plasma variables
after a variety of single and mixed meals. For comparison, model simulations are
presented alongside sample experimental data in section 3.1. As plasma is the main
transport system between compartments, the concentrations of key carbohydrate and
lipid molecules in the plasma gives confidence in the model for plasma and other
tissues.
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3.1. Plasma variables
Cruz et al [11] simultaneously measure changes in plasma glucose, insulin, NEFA,
and TAG, at multiple time points over an interval of 0 to 480 minutes in response to
a single mixed meal. Meal composition is broken down as 52% fat, 40% CHO and 8%
protein. The time scales for absorption of metabolites, the parameters βF and βG in
(1), are determined by peak absorption time after ingestion; 180 minutes for fat, and
35 minutes for carbohydrates. Figure 2 compares model simulations to experimental
data.
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Figure 2: The evolution of plasma variables for a single meal compared to model simulations:
Experimental data (red asterisk), model predictions (blue). All variables have units mmol/l, except
insulin (10−7 mmol/l).
Reasonable agreement is shown between experimental data and model simulations for
both plasma glucose and insulin. Glucose rises after the mixed meal as it is absorbed
from the gut, and a concomitant rise in plasma insulin is observed. Both metabolites
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return to near steady state over a time of 240 minutes. Qualitative agreement is
shown between simulations and experimental data for plasma NEFA. Concentrations
initially decrease in response to the mixed meal, the main change observed occurring
in the inhibition of adipose tissue lipolysis. After insulin recovers, NEFA initially
overshoots its steady state as the action of LPL on circulating chylomicrons leaks fatty
acids into the plasma. The likely difference between our simulations and experimental
data occurs due to the up-regulation of LPL in response to insulin occurs with a delay
of about 4 hours which is not included in the model. As this is timed to occur when
chylomicron concentrations are peaking in the system, the overshoot would be higher
than predicted by our model. Had plasma NEFA been measured for longer in the
experiment, we would expect it to return to steady state concentration within hours,
in the same manner as our simulations.
3.2. Nonplasma variables
Variables for which we have no experimental data to compare against are plotted and
discussed in the appendix Appendix A
3.3. Comparison with 24 hour meal data
To consider longer timescales, we begin by simulating a typical day with 3 meals.
A different data set [24] (provided by the Oxford Lipid Metabolism group) is used
for these longer experiments. Three isocaloric meals were fed at intervals of 5 hours
apart, with frequent sampling of plasma insulin, glucose, NEFA and TAG. The car-
bohydrate and fat composition of each meal is summarised in Table 4, and complete
experimental protocol for this data set is detailed in Hodson et al [24]. Experimental
results are shown alongside model predictions for the 24 hour period in Figure 3.
Breakfast Lunch Dinner
Carbohydrate 108.2g 108.7g 106.2g
of which sugars 65.8g 24.7g 52.5g
Fat 36.0g 34.3g 33.1g
Table 4: Meal composition
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Figure 3: The evolution of plasma variables over 24 hours, meals given at times 0, 5, 10 hours.
Experimental data (red asterisk), model predictions (blue). All variables have units mmol/l, except
insulin (10−7 mmol/l).
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Model simulations provide an excellent fit to the glucose and insulin ex-
perimental data during the first meal (0-300 minutes duration). The qual-
itative fit to glucose breaks down during the second and third meals where
the model fails to capture an additional secondary spike of glucose, and a
longer tail in the postprandial period. Additionally, there is a qualitative
change in the peak insulin concentration at meal two not predicted by
the model. This suggests that a model to accurately predict changes in
metabolite concentrations over a longer-term would need some memory of
earlier meals.
Despite the similarity in meal composition, both in terms of energy density and sub-
strate composition, a vastly different response in plasma insulin is observed between
the first and third meals compared to the second. However, similar responses in
plasma glucose levels are observed in the three meals, suggesting that lower insulin
concentrations were needed for effective disposal of plasma glucose in the second meal.
The difference in the glucose/insulin response between meals can be contrasted better
in the phase-plane diagram shown in Figure 4. The first meal produces the highest
insulin spike, and whilst the other two meals produce similar glucose spikes, the sec-
ond meal produces a significantly lower insulin spike, before plasma glucose returns
to a slightly higher basal level. Following the third meal, the glucose returns to an
even more elevated level, showing an increase in insensitivity to glucose/insulin by
the body, through the day.
The model predicts NEFA well at early times, but the accuracy of fit to experimental
data declines for successive meals. In particular, entering the fasting period after the
third meal (approximately 6 hours after ingestion), the model predicts an overshoot
in NEFA, whilst the experimental NEFA remains suppressed longer (approximately
11 hours after ingestion of meal). This is almost certainly due to plasma insulin re-
maining elevated above normal fasting values.
Experimental TAG concentrations during the first meal show reasonable
agreement with the model. Again, the fit breaks down during the second
meal. This could potentially be explained by a lack of LPL activation since
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Figure 4: Insulin-glucose phase-plane for experimental data of mixed meals. Top left first meal
(solid line), top right second meal (dashed line), bottom left third meal (dotted line), bottom right
all meals
corresponding insulin concentrations are low, although other factors such
as insulin regulated release of VLDL from the liver are likely to impact fit
as well. Following the third meal, the decrease in TAG occurs at a rate
much quick than is predicted by the model.
It is clear that the metabolic response to successive meals differs significantly to that
of a single meal after a fast; something that the model fails to predict. Due to the
strong influence insulin has throughout lipid metabolism, improved results would be
obtained if we could reproduce the insulin response observed. Without additional
modelling of insulin/glucose dynamics, we can predict the true effect of insulin on
lipid metabolism by using the experimental insulin and glucose data as inputs to our
model.
3.4. Data fitting of 24 hours meal pattern
We consider the accuracy of the model in predicting plasma NEFA and liver lipids
using the experimentally derived glucose and insulin to infer the other variables.
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A cubic interpolating spline was fitted to the experimental for plasma glucose and
insulin data (with ghost points of neighbouring splines at 270 minutes at 570 minutes),
whilst all other variables remained the same (Figure 5). New simulations with spline
approximations replacing equations (26) and (27) show better agreement with plasma
NEFA (a major determinant of liver lipids). Under these conditions, hepatic TAG
differs significantly in the fasted period (Figure 6), showing an emptying of lipid in
the liver, rather than the build up of lipid seen in the initial simulation.
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Figure 5: Top: Experimental forced-fit model of insulin concentration I(t), Bottom:
New prediction of plasma NEFA AB(t) plotted against time. Experimental data (red
asterisk), forced-fit model predictions (blue line).
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Figure 6: Comparison of initial simulation of hepatic TAG (solid blue line) with new comparison of
hepatic TAG (dashed red line).
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4. Discussion
Our study of hepatic lipid metabolism has led us to produce a large compartmental
ODE system covering multiple chemical species in multiple tissues. This has resulted
in a system which is less detailed than many other single-tissue models available in
the literature, but that integrates the non-hepatic tissues and pathways relevant to
understanding the pathogenesis of hepatic steatosis.
Our initial single meal simulations show good agreement with experimental data, but
the comparison with multiple meals is less accurate. The decreased insulin response in
the second meal compared to the first could occur for a number of reasons. Although
the amount of carbohydrate ingested is the same across all three meals, the ratio
of simple to complex sugars varies. However, we have investigated this (analysis not
shown here [47]) and found that differences in the release rate of sugar from the gut do
not account for the differences observed. This differing response could be explained by
the first meal ’priming’ the body to deal with carbohydrates, and so not requiring the
same concentration of insulin to suppress plasma glucose. It may be speculated that,
changes in insulin sensitivity after multiple meals provide the body with some ‘long
term memory’ of previous metabolic events. However, the mechanisms underlying
such an effect (should it actually exist) remain to be explored.
Simulations suggested that lower GI carbohydrate diets have the effect of reducing
hepatic triglycerides, see Figure 7. In the model, this was achieved by staying in
the postprandial-period longer than that of a high GI diet. This response is likely
due to the nonlinear reduction in adipose free fatty acid release from the moderate
hyperinsulinemia. In addition, model simulations suggested dietary composition has
a significant impact on the amount of fat accumulated in the liver, with a higher per-
centage of fat in the diet leading to higher concentrations of TAG in the liver. This
is due to both the increased delivery directly from chylomicrons and the associated
NEFA spill-over, as well as the reduced suppression of NEFA release by adipose tissue
from a lower insulin response.
The model suffers from several limitations. Protein interactions have been ignored,
which, far from being separate from carbohydrate and fat metabolism, influence key
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Figure 7: Hepatic TAG vs time for a 3-meal high GI (βG = 60) and low (βG = 80) GI diet.
processes through the production of pyruvate from protein precursors (e.g. lactate
and alanine). Absorption of carbohydrates and fat by the gut is known to be affected
by the quantity of protein ingested. We have assumed a constant energy expenditure
which may be unrealistic given the activity levels vary significantly over 24 hours.
This may in part explain why our simulations for hepatic TAG show qualitatively
different behaviour between the first 16 hours, and the last 8 hours. We have as-
sumed processes that are up-regulated by glucagon are down-regulated by insulin
and vice versa. In reality, high concentrations of insulin are not always matched by
low levels of glucagon. Glucagon concentrations were not measured in the three meal
data. Diet induced thermogenesis has been ignored, so energy consumption in the
processing of carbohydrates and fats has not been fully taken into account. Inter-
mediary metabolites such as those in the glycolytic pathway have been ignored, as
non-fasting data is difficult to obtain, and they are not of primary concern to the
model. As the composition of sugars was not available in our experimental data, we
have assumed all carbohydrates are broken down to glucose. Had we factored in that
a (small) proportion of these carbohydrates would be fructose, the insulin and hep-
atic TAG responses would have differed. Finally, we accepted that a delay of 4 hours
in the activation of LPL would produce a better fit of the NEFA component of the
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model, however, we choose not to include this as the introduction of delay-differential
equations would hinder future analysis.
More data is required to validate our model. We have relied upon simultaneous mea-
surements of plasma TAG and plasma NEFA as an indicator of uptake and release
rates of hepatic lipid, to infer net change in concentration. However, since DNL and
beta-oxidation were not measured, we are missing the complete information required
to infer changes in hepatic TAG indirectly. Frequent NMR imaging of hepatic TAG
would provide a direct method to validate liver fat changes in response to diet. Com-
bined with frequent samples of plasma metabolites, this would provide ideal data to
validate our model.
The model we have created does not describe every process of energy metabolism in
detail, it is rather an attempt to describe the factors that effect triglyceride accumu-
lation in the liver using physiological mechanisms. It therefore provides a framework
to study these mechanisms that are likely involved in the pathogenesis of hepatic
steatosis. Given that insulin resistance is the most reproducible factor in NAFLD, in
future work we intend to simulate varying degrees of resistance in single and multiple
tissues in this model to investigate likely disease progression.
The results here emphasise the difficulty of predicting fat metabolism without a
strong understanding of insulin; therefore, the interaction of carbohydrates and lipids
through digestion and absorption to storage and oxidation in the body is relevant.
The importance of meal timing has also been shown; our own simulations indicate an
interaction when the body is not allowed to return to the fasting steady state before
a new meal is fed, however the experimental data has shown this to be a far greater
deviation than previously predicted.
The work here provides a framework to study the effects of insulin resistance in mul-
tiple tissues on the accumulation of TAG in the liver. Whilst the plasma behaviour
could be reproduced with a smaller number of equations, this larger system incorpo-
rates the detail required to study whole body effects from singular processes within
individual tissues. We intend to study the parameter adaptations required in the
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transition from healthy to insulin resistant states, and whether this is necessary for
the increased deposition of liver fat seen in individuals with hepatic steatosis.
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Appendix A. Supplementary graphs
Variables for which we have no experimental data to compare against are illustrated
for a complete day in which three identical mixed meals are simulated, five hours
apart for a typical western diet. Each meal comprises 105 g carbohydrate (absorption
rate βG = βF = 45 minutes in (1) with αG + αF = 105g/β
2) and 35g fat (absorption
rate βT = 180 minutes, with αT = 35g/β
2
T ). Model predictions for variables are
shown in figures A.8, A.9, and A.10. Of particular interest is the observation that
hepatic TAG initially decreases following a fatty meal. One explanation for this
is that, since fat is ingested alongside carbohydrates in a mixed meal, secretion of
insulin suppresses adipose lipolysis to a greater extent than hepatic TAG secretion
is suppressed. Whilst this is an oversimplification, given the number of pathways
affecting hepatic TAG concentration, a large quantity of carbohydrates can almost
completely shut off adipose lipolysis (95% reduction), reducing plasma NEFA (and
therefore hepatic uptake) substantially.
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Figure A.8: The evolution of adipose associated variables over 24 hours, meals given at times 0, 5,
10 hours. First column AA, GA. Second column TA, LA. All variables have units mmol/l.
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Figure A.9: The evolution of muscle associated variables over 24 hours, meals given at times 0, 5, 10
hours. First column GM , PM , AM . Second column YM , RM , TM . All variables have units mmol/l.
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